rilonacept (Arcalyst)
Jump to navigation
Jump to search
Indications
- inflammation in cryopyrin-associated periodic syndromes
- refractory gout
- resolution & prevention of recurrent pericarditis[3]
Contraindications
Monitor
- complete blood count (CBC) baseline & every 3 months[2]
Mechanism of action
- dual IL-beta receptors chimerically attached to Ig Fc fragment
- interleukin-1 receptor antagonist
Management
- whenever possible bring patients up to date on vaccinations prior to initiating biologic immunosuppressive agent[2]
Notes
- Manufacturer: Regeneron
- more expensive IL-1 inhibitor
More general terms
Additional terms
References
- ↑ Prescriber's Letter 16(2): 2009 New Drugs Approved by the FDA in 2008 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 2.2 2.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19. American College of Physicians, Philadelphia 2012, 2015, 2018, 2022
- ↑ 3.0 3.1 Klein AL et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 2020 Nov 16; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33200890 https://www.nejm.org/doi/10.1056/NEJMoa2027892